News|Articles|July 2, 2026

9 Endocrinology Headlines You Missed in Q2 2026

Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 3 months.

The second quarter of 2026 saw an influx of critical approvals from the US Food and Drug Administration (FDA) and a slew of major conferences including the American Diabetes Association (ADA) Scientific Sessions and the Endocrine Society (ENDO) Annual Meeting. Between inhaled insulin’s approval in pediatric patients and the topline efficacy of crinecerfont and retatrutide, all manner of drugs for type 1 diabetes (T1D), type 2 diabetes (T2D), and obesity received major updates.